Implementation of Modern GMP Aspects: Revision of the Annex 2 of the EC GMP Guide as an Example

GMP News
15 November 2007
 

Implementation of Modern GMP Aspects: Revision of the Annex 2 of the EC GMP Guide as an Example


The GMP environment is currently changing. Not only the US Food & Drug Administration modifies its GMP regulations, but also the European Medicines Agency (EMEA) has taken up an ambitious revision programme for this year (see also GMP-News from 2 November 2007). As an “outcome” the EMEA recently issued the drafted revision of the Annex 2 of the EC GMP Guide for (see also GMP-News from 9 October 2007).

The draft clearly shows the modern GMP aspects incorporated – as, for instance, risk management. ICH Q9 (Quality Risk Management) is currently discussed everywhere. The EC GMP Guide chapter 1 was modified accordingly, and the Community Procedures are currently revised with regard to risk management also. ICH Q9 itself will supposedly be implemented as Annex 20.

The draft of Annex 2 now also reinforces the requirement for risk based decisions. This affects for example

  • The access of personnel in the manufacture of biotech products,
  • The management of aseptic processes and
  • Tests with regard to cross contamination.

Other changes currently discussed apply to the EC GMP Guide chapters 3 and 5 concerning “dedicated facilities/dedicated equipment”. The Annex 2 draft requires e.g., to take “dedicated equipment/facilities“ into account to be able to reproduce products and avoid cross contaminations. Risk management is present here as well. It also addresses a possible conflict with requirements regarding work safety. In the changes to the chapters 3 and 5 themselves risk management will also be a main focus.

A well-known issue – validation/qualification – will still remain. For instance, the draft addresses validation-related requirements like

  • Validation of decontamination,
  • Validation of air vent filters (for their life span
  • Processes validation (specifically mentioned are allergen and recombinant products, monoclonal anti bodies and gene therapeutics
  • Validation of sterilisation, disinfection, virus removal and –inactivation
  • Requalification of the irradiation
  • Validation of hold time
  • Validation of purification
  • Cleaning Validation (specifically mentioned are gene therapeutics)

The Annex 2 draft can be used as indicator for “modern GMP”. The trend clearly goes toward risk based decisions which the authorities demand from pharmaceutical companies – however, paying attention to validation/qualification at the same time though.

Get answers to still many open questions with regard to cleaning validation in the 2-day education course Cleaning Validation in Vienna, Austria, from 27-28 May 2008.

Conference Tip:
International Bio-Conference Bio Production Forum – Fill and Finish for Biopharmaceuticals in Schaffhausen, Switzerland, from 28-30 November 2007.

 

Author:
Sven Pommeranz
On behalf of the European Compliance Academy (ECA)


 

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK